TY - JOUR
T1 - Correction to: Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: influence of the disease severity and therapy on the ovarian reserve (Endocrine, (2019), 63, 2, (369-375), 10.1007/s12020-018-1783-1)
AU - Di Mario, Clara
AU - Petricca, Luca
AU - Gigante, Maria Rita
AU - Barini, Angelina
AU - Barini, Angelina
AU - Barini, Antonella
AU - Varriano, Valentina
AU - Paglionico, Annamaria
AU - Cattani Franchi, Paola
AU - Ferraccioli, Gianfranco
AU - Tolusso, Barbara
AU - Gremese, Elisa
PY - 2019
Y1 - 2019
N2 - Purpose Systemic lupus erythematosus (SLE) mainly affects childbearing age women and pharmacological treatments may
negatively influence the ovarian reserve. Anti-Müllerian hormone (AMH) could be a good biomarker for ovarian reserve.
Methods AMH serum levels were assessed in 86 consecutive SLE female patients with regular menstrual cycle compared
with 44 aged matched healthy controls. Clinical and demographic characteristics, disease duration, pattern of organ
involvement, and previous and current therapies were recorded.
Results AMH levels were comparable between patients and controls (4.2 ± 3.1 ng/ml vs. 5.0 ± 3.1 ng/ml, p = 0.21).
According to disease severity, AMH levels were lower in SLE patients with major organ involvement than in controls
(3.8 ± 2.7 ng/ml vs. 5.0 ± 3.1 ng/ml, p = 0.08); no difference was found between SLE patients with mild organ involvement
(4.5 ± 3.4 ng/ml) and controls (p = 0.43). Grouping patients based on the pharmacological treatments, AMH serum levels
did not differ among SLE patients treated with antimalarials only (4.7 ± 3.3 ng/ml), conventional disease-modifying antirheumatic drugs (cDMARDs) only (4.8 ± 3.2 ng/ml), cDMARDs and antimalarials (3.9 ± 2.9 ng/ml) or cyclophosphamide
(CYC) only (4.9 ± 3.9 ng/ml), compared to controls, but patients sequentially treated with cDMARDs and CYC, had
significantly lower AMH serum levels than controls (p = 0.01).
Conclusions SLE patients showed comparable AMH levels than controls, however, a reduction of the ovarian reserve was
associated with sequentially therapy with CYC and cDMARDs and with the disease severity. AMH could be a sensitive and
specific biomarker of ovarian reserve in SLE and it could be useful for therapeutic strategy and family planning.
AB - Purpose Systemic lupus erythematosus (SLE) mainly affects childbearing age women and pharmacological treatments may
negatively influence the ovarian reserve. Anti-Müllerian hormone (AMH) could be a good biomarker for ovarian reserve.
Methods AMH serum levels were assessed in 86 consecutive SLE female patients with regular menstrual cycle compared
with 44 aged matched healthy controls. Clinical and demographic characteristics, disease duration, pattern of organ
involvement, and previous and current therapies were recorded.
Results AMH levels were comparable between patients and controls (4.2 ± 3.1 ng/ml vs. 5.0 ± 3.1 ng/ml, p = 0.21).
According to disease severity, AMH levels were lower in SLE patients with major organ involvement than in controls
(3.8 ± 2.7 ng/ml vs. 5.0 ± 3.1 ng/ml, p = 0.08); no difference was found between SLE patients with mild organ involvement
(4.5 ± 3.4 ng/ml) and controls (p = 0.43). Grouping patients based on the pharmacological treatments, AMH serum levels
did not differ among SLE patients treated with antimalarials only (4.7 ± 3.3 ng/ml), conventional disease-modifying antirheumatic drugs (cDMARDs) only (4.8 ± 3.2 ng/ml), cDMARDs and antimalarials (3.9 ± 2.9 ng/ml) or cyclophosphamide
(CYC) only (4.9 ± 3.9 ng/ml), compared to controls, but patients sequentially treated with cDMARDs and CYC, had
significantly lower AMH serum levels than controls (p = 0.01).
Conclusions SLE patients showed comparable AMH levels than controls, however, a reduction of the ovarian reserve was
associated with sequentially therapy with CYC and cDMARDs and with the disease severity. AMH could be a sensitive and
specific biomarker of ovarian reserve in SLE and it could be useful for therapeutic strategy and family planning.
KW - Anti-Müllerian hormone
KW - systemic lupus erythematosus
KW - Anti-Müllerian hormone
KW - systemic lupus erythematosus
UR - http://hdl.handle.net/10807/132620
UR - http://www.springer.com/humana+press/journal/12020
U2 - 10.1007/s12020-018-1811-1
DO - 10.1007/s12020-018-1811-1
M3 - Article
SN - 1355-008X
VL - 63
SP - 405
EP - 405
JO - Endocrine
JF - Endocrine
ER -